Ani Pharmaceuticals (ANIP) Payables (2016 - 2025)
Historic Payables for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $69.8 million.
- Ani Pharmaceuticals' Payables rose 1462.47% to $69.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.8 million, marking a year-over-year increase of 1462.47%. This contributed to the annual value of $45.7 million for FY2024, which is 2446.09% up from last year.
- As of Q3 2025, Ani Pharmaceuticals' Payables stood at $69.8 million, which was up 1462.47% from $54.6 million recorded in Q2 2025.
- Ani Pharmaceuticals' Payables' 5-year high stood at $69.8 million during Q3 2025, with a 5-year trough of $11.5 million in Q3 2021.
- Moreover, its 5-year median value for Payables was $32.7 million (2023), whereas its average is $35.4 million.
- As far as peak fluctuations go, Ani Pharmaceuticals' Payables crashed by 1446.51% in 2021, and later skyrocketed by 11299.99% in 2022.
- Ani Pharmaceuticals' Payables (Quarter) stood at $23.0 million in 2021, then increased by 27.6% to $29.3 million in 2022, then rose by 25.18% to $36.7 million in 2023, then grew by 24.46% to $45.7 million in 2024, then soared by 52.87% to $69.8 million in 2025.
- Its last three reported values are $69.8 million in Q3 2025, $54.6 million for Q2 2025, and $53.1 million during Q1 2025.